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Robert J. Lederman, MD*I deas are important. Without ideas, nothing canhappen. However, most ideas die before any-thing useful develops from them. Interventional
cardiology was born from ideas and prospers from
ideas that are translated into useful medical innova-
tions. I was reminded about this gulf between basic
ideas and useful discovery when I heard of the death
of my friend, Jack Vogel after a long illness. Jack was
addicted to new ideas and always tried to promote
them at his Snowmass course and at the Santa
Barbara courses speciﬁcally designed to bring the
latest concepts in interventional cardiology. In the
late 1980s, a time we called the new device era, every
innovator was invited to those Santa Barbara meet-
ings and a similar one put on by Michel Bertrand in
Monaco. We saw all kinds of devices including direc-
tional atherectomy, extraction atherectomy, rota-
tional atherectomy, porous drug-eluting balloons,
brachytherapy devices, multiple laser approaches
including selective lasers to identify plaque and to
ablate only abnormal tissues, balloon lasers, micro-
wave angioplasty, spark erosion, early stents, and
aortic balloon valvuloplasty. These were a few of
the device ideas put forth in these conferences and
in a book edited by Jack and myself (1). Many of these
ideas died and appropriately so, but others took de-
cades to reach clinical application. The bioabsorbable
stent, an idea ﬁrst suggested to me in 1986 by Jack
Whitehead, founder of the institute at the Massachu-
setts Institute of Technology bearing his name, has
now, almost 30 years later, gained the status of clin-
ical application and critical examination. This wide
chasm between ideas and clinical application is the
domain of translational research. About a year ago, Iitute, Bethesda,received a letter from Dr. Robert Lederman of the Na-
tional Heart, Lung, and Blood Institute (NHLBI). This
is what he said:
In April 2013, JACC published a letter describing
the transcaval approach for TAVR [transcatheter
aortic valve replacement] that NHLBI conceived
and tested in animals (2). That publication con-
nected Henry Ford investigators to NHLBI and
led to clinical translation of a promising new
method (3). Unfortunately, journal space appears
to be declining for the animal feasibility experi-
ments required to develop such novel treat-
ments, and editorial boards increasingly
downplay pre-clinical interventional work as
“science fair” novelties not immediately appli-
cable to clinical practice. I believe otherwise.
First, every talented physician has creative ideas
but perhaps not the right opportunity to develop
them. Pre-clinical “idea papers” inspire readers
and sometimes connect them directly with au-
thors, as in the transcaval experience. New con-
cepts inspire clinicians to try new approaches,
engineers to invent new devices, and industry to
develop new products.
Second, trainees need to see that it is possible to
contribute wholly new and immature concepts in
interventional cardiology beyond testing others’
commercial products, and without genuﬂecting to
commercial interests.
Third, translation from concept to clinical medical
device is arduous. Obstacles, whether ﬁnancial,
academic, or regulatory, are numerous. Trans-
lating pre-clinical feasibility into patients requires
funding, and publication is a key step towards
obtaining funding. Indeed selection for publica-
tion is akin to triage for funding.
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1139Herein lies the problem. When publication
thresholds are so high, important work gets
missed. NHLBI’s Michael Lauer recently reported
the astonishing observation that the most highly
ranked investigator-initiated NHLBI grant appli-
cations do not necessarily generate the most
highly cited publications (4). This suggests that as
selection criteria become too restrictive, they lose
discriminative value.
Perhaps JACC can offer a solution, such as an
online-only “early innovation” section. Such a
feature would promote translational science and
help bridge the funding gaps that separate proof-
of-concept from ﬁrst-human-testing of new
treatments.
Despite tight space and tight budgets, it is critical
to make new space for innovative pre-clinical
cardiovascular “idea papers.”
Well, Robert, the JACC family of journals is now
going to address this issue. A new journal dedicated
to translational research will provide a home for
some of these pre-clinical ideas and discoveries.
JACC: Basic Translational Research will be an open-
access journal that is online only and will providea venue for many papers now judged to be too
early for JACC or the other members of the family,
such as JACC: Cardiovascular Interventions. Obvi-
ously the submissions sought will cover the entire
spectrum of cardiovascular medicine including
drug therapy, cell therapy, genomics, and so on. Of
special interest to us, however, will be the device
and technique papers that we have not had space
for in the past. Some have asked whether JACC
and the other JACC journals will continue to publish
translational papers, and the answer is yes. But,
the new journal will provide an opportunity to
bring many more new ideas with translational
activity or potential to the clinical, as well as the
scientiﬁc, communities. This publication is one
aspect of the needed empowerment of translational
research, and I will discuss another in a subsequent
letter, but hopefully this will be a constructive step
to reduce what has, in the past, been “lost in
translation.”
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